The overall goal of the program described in this competing submission proposal (CA47179-15) is to continue an integrated multidisciplinary approach to the investigation of the biology, pathogenesis, progression and natural history of soft tissue sarcoma and then use this knowledge to identify novel therapeutic targets that can be tested clinically in phase I and II clinical trials. The specific goals are to: 1) improve diagnosis and prognostication 2) identify new molecular and biochemical targets in sarcoma through gene discovery and pathway analysis 3) develop new targeted molecular therapeutics and 4) validate molecular and biochemical targets in clinical studies. To achieve these goals we have marshaled an integrated, multidisciplinary group of investigators all armed with a unique resource, a clinicopathological and outcomes database prospectively collected over a 23 year period containing over 6486 patients treated for soft tissue sarcoma at MSKCC. This database has been linked to an institutional tissue bank for the past 12 years and, for the past 3 years, to a comprehensive tissue procurement process for establishment of primary sarcoma cell lines and mouse xenograft models of human sarcoma. This renewal application contains substantial changes with the addition of two entirely new projects, which interact closely with the two continuing projects and the establishment of a new bioinformatics core. In Project 1, a new initiative in liposarcoma biology, we will use an integrated gene expression and NMR biochemical analysis to improve diagnosis and prognostication and to identify new therapeutic targets and cellular pathways critical to liposarcoma tumorigenesis. In Project 2, we will study how the PTEN/AKT signaling network regulates genes in the RB and p53 pathway to control cell cycle and apoptosis. Project 3, an entirely new project on development of targeted therapeutics, will identify new therapies that modulate the cell cycle and translate these preclinical discoveries into clinical cancer therapy for sarcoma patients. In Project 4, we will continue to define the molecular genetics of synovial sarcoma with a particular emphasis on identification of new molecular targets through mutational analysis of differentially expressed tyrosine kinase genes. These 4 projects are supported by 3 cores: Administrative, Pathology, and Bioinformatics. The highly integrated collaboration between all projects and cores will ensure maximum productivity and will enhance molecular and biochemical target identification through gene discovery and pathway analysis. This information will then be used to develop new targeted molecular therapeutics for soft tissue sarcoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047179-19
Application #
7872951
Study Section
Subcommittee G - Education (NCI)
Program Officer
Timmer, William C
Project Start
1997-05-16
Project End
2012-06-30
Budget Start
2010-08-01
Budget End
2012-06-30
Support Year
19
Fiscal Year
2010
Total Cost
$1,805,746
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452
Kao, Yu-Chien; Sung, Yun-Shao; Zhang, Lei et al. (2017) Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1. Genes Chromosomes Cancer 56:42-50
Seifert, Adrian M; Zeng, Shan; Zhang, Jennifer Q et al. (2017) PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res 23:454-465
Argani, Pedram; Zhang, Lei; Reuter, Victor E et al. (2017) RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. Am J Surg Pathol 41:655-662
Argani, Pedram; Zhong, Minghao; Reuter, Victor E et al. (2016) TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol 40:723-37
Tan, Marcus C B; Brennan, Murray F; Kuk, Deborah et al. (2016) Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg 263:593-600
Specht, Katja; Zhang, Lei; Sung, Yun-Shao et al. (2016) Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 40:433-42
Huang, Shih-Chiang; Ghossein, Ronald A; Bishop, Justin A et al. (2016) Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. Am J Surg Pathol 40:51-9
Dickson, Mark A; Schwartz, Gary K; Keohan, Mary Louise et al. (2016) Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA Oncol 2:937-40

Showing the most recent 10 out of 336 publications